Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease

NCT00760435 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

196

Enrollment

OTHER

Sponsor class

Conditions

Kawasaki Disease

Interventions

DRUG: Infliximab
DRUG: Placebo

Sponsor

University of California, San Diego

Collaborators

[object Object]